197732-79-9

Upstream product

• 123158-61-2 3-(2-propenyl)nitrobenzene 
• 119273-79-9 β-methyl-3-nitrostyrene 
• 99-61-6 3-nitro-benzaldehyde 
• 591-19-5 m-Bromoaniline 
• 103-65-1 phenylpropane 
• 97111-27-8 acetic acid-(3-propionyl-anilide) 
• 1197-05-3 1-(3-amino-phenyl)-propan-1-one 
• 17408-16-1 3'-nitropropiophenone 
• 73585-59-8 m-nitropropylbenzene 

Downstream Products

• 103858-40-8 acetic acid-(3-propyl-anilide) 
• 151963-09-6 3-propylbenzonitrile 
• 7661-59-8 7-propylquinoline 
• 1350914-61-2 C₂₀H₁₇F₃N₂O₂ 
• 875231-51-9 1-(3-propyl-phenyl)-propan-1-one 
• 17171-72-1 1,3-dipropyl-benzene 

Relevant academic research and scientific papers

Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid

The YAP-TEAD transcriptional complex is responsible for the expression of genes that regulate cancer cell growth and proliferation. Dysregulation of the Hippo pathway due to overexpression of TEAD has been reported in a wide range of cancers. Inhibition of TEAD represses the expression of associated genes, demonstrating the value of this transcription factor for the development of novel anti-cancer therapies. We report herein the design, synthesis and biological evaluation of LM98, a flufenamic acid analogue. LM98 shows strong affinity to TEAD, inhibits its autopalmitoylation and reduces the YAP-TEAD transcriptional activity. Binding of LM98 to TEAD was supported by 19F-NMR studies while co-crystallization experiments confirmed that LM98 is anchored within the palmitic acid pocket of TEAD. LM98 reduces the expression of CTGF and Cyr61, inhibits MDA-MB-231 breast cancer cell migration and arrests cell cycling in the S phase during cell division.

COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders

4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, and their pharmaceutically acceptable salts, are potent specific antagonists of N-methyl-D-aspartate (NMDA) receptors and are therefore useful in the treatment of neurodegenerative disorders. 4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, other than carboxy or C 1-6 alkoxycarbonyl, are novel compounds, as also are compounds of formula II STR1 wherein R 2 represents carboxy or a group convertible thereto in vivo, R 6 is hydrogen and R 5 and R 7 represent C 1-6 alkyl or halogen, provided that R 5 and R 7 are not simultaneously chlorine or simultaneously bromine; a process for preparing the novel compounds is described, as also are pharmaceutical compositions containing the novel compounds.